NEXVIAZYME

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Pompe disease

Dosage

Children: Refer to product-specific guidelines for dosing in paediatric patients, which should be assessed based on weight and clinical condition.

Adults: Refer to product-specific guidelines for dosing in adults, which are typically determined based on the severity of the disease and clinical response.

Mechanism of action

Avalglucosidase works by providing a recombinant form of the enzyme acid alpha-glucosidase, which is responsible for hydrolyzing glycogen into glucose within lysosomes. By supplying the deficient enzyme, avalglucosidase facilitates the breakdown of glycogen, reducing its accumulation in muscle cells and other tissues, thus ameliorating the symptoms of Pompe disease.

Pharmacodynamics

The pharmacodynamics of avalglucosidase involve its ability to improve muscle strength and function by enhancing glycogen metabolism. The enzyme acts on lysosomal glycogen, leading to a decrease in lysosomal storage and associated cellular damage. Clinical studies have shown improvements in respiratory function, motor skills, and overall physical ability in patients receiving enzyme replacement therapy with avalglucosidase.

Pharmacokinetics

Avalglucosidase is administered intravenously and has a distribution profile that indicates it reaches target tissues rapidly. It is expected to be metabolized in the body similar to other proteins, with a half-life that allows for regular dosing schedules. The pharmacokinetics may vary based on patient-specific factors, including age, disease severity, and prior treatment history.

Adverse effects

• Infusion-related reactions
• Headache
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Rash
• Fatigue

Precautions

• Monitor for infusion-related reactions during and after administration
• Use caution in patients with a history of hypersensitivity to the drug or its components
• Assess for potential underlying respiratory issues if respiratory symptoms occur

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Avalglucosidase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether avalglucosidase is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store vials in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light.

Formulations

• Avalglucosidase 10 mg/mL solution for infusion